The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
The news of Covid vaccines has delighted many. But not Argonaut Capital's Barry Norris. He tells Merryn why vaccines aren't the panacea people think t…
3 Dec 2020
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
More good news as AstraZeneca finds a third Covid vaccine
Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
Ugur Sahin and Özlem Türeci are an unassuming Turkish-German couple who had already made their fortune as biotech entrepreneurs when a strange new vi…
21 Nov 2020
Moderna’s “stunning” second vaccine
Moderna’s “stunning” second vaccine
America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports
19 Nov 2020
Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?
Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?
A vaccine that appears so far to be safe and effective is making its way through the final trials before commercialisation. There are reasons to be ch…
12 Nov 2020
Novo Nordisk: Denmark’s dominant drug maker
Novo Nordisk: Denmark’s dominant drug maker
Novo Nordisk leads the global market in diabetes treatments and looks a solid long-term buy, says Dr Mike Tubbs.
4 Nov 2020
Subscribe to MoneyWeek and get your first six issues FREE
Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
How to profit from the development of new auto-immune disease drugs
How to profit from the development of new auto-immune disease drugs
Some debilitating conditions are caused by the body’s defence mechanism going awry. Dr Mike Tubbs appraises a key subsector of the pharmaceuticals mar…
29 Oct 2020
Cash injection: join the hunt for a coronavirus vaccine
Cash injection: join the hunt for a coronavirus vaccine
Covid-19 has renewed interest in preventing the spread of viruses. But the appeal of this rapidly growing sub-sector of the pharmaceuticals market sho…
29 Oct 2020
The MoneyWeek Podcast: the accelerating revolution in healthcare
The MoneyWeek Podcast: the accelerating revolution in healthcare
Merryn talks to Dr Paul Jordan, Anna Macdonald, and Dr Gareth Blades of Amati Global investors about some of their favourite small UK companies - incl…
1 Oct 2020
The race for a coronavirus vaccine heats up
The race for a coronavirus vaccine heats up
Biotech shares, led by AstraZeneca, are lifted in the race to come up with a coronavirus vaccine.
28 Aug 2020
Profit from the fast growth of the haircare industry
Profit from the fast growth of the haircare industry
Our society has become much more image-conscious, while new consumers worldwide want to look good too. From shampoos to new potential cures for baldne…
6 Aug 2020
Which Covid-19 vaccines look likely to be the best bets?
Which Covid-19 vaccines look likely to be the best bets?
The race to produce a treatment to prevent Covid-19 has hundreds of entrants. How should investors approach it? Matthew Partridge reports.
24 Jul 2020
Syncona: a biotech trust that's going for a song
Syncona: a biotech trust that's going for a song
Syncona is an investment trust that invests in promising, privately-held biotechnology companies. It looks too cheap.
15 Jun 2020
AstraZeneca mulls €240bn mega-merger with Gilead Sciences
AstraZeneca mulls €240bn mega-merger with Gilead Sciences
Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.
11 Jun 2020
Compound interest: the eighth wonder of the world
Compound interest: the eighth wonder of the world
Setting up a pharmaceuticals trust in the mid-1990s taught Max King the power of compounding
26 May 2020
The race to defeat the superbugs has just begun
The race to defeat the superbugs has just begun
Drug-resistant bacteria are far more dangerous than Covid-19. So will we soon see major progress in developing new antibiotics? It will be a long slog…
22 May 2020
Biotech firm's shares soar on hopes of a Covid-19 vaccine
Biotech firm's shares soar on hopes of a Covid-19 vaccine
Shares in biotech firm Moderna have rocketed after an early-stage trial of a drug showed promise. But they could soon return to earth. Matthew Partrid…
21 May 2020
Look beyond Merck’s miracle cancer drug for profits
Look beyond Merck’s miracle cancer drug for profits
Keytruda, Merk’s cancer treatment, is a winner. But it’s not the only reason to be bullish on the pharma group.
18 May 2020
Three stocks to profit from the healthcare innovation revolution
Three stocks to profit from the healthcare innovation revolution
Anthony Ginsberg, manager of the HAN-GINS Indxx Healthcare Innovation UCITS ETF, picks three of his favourite healthcare stocks to buy now.
11 May 2020
Three biotech stocks to buy for healthy long-term returns
Three biotech stocks to buy for healthy long-term returns
Professional investor Marek Poszepczynki of the International Biotechnology Trust picks three biotech stocks with strong balance sheets that look well…
27 Apr 2020
Gilead's anti-viral expertise will stand it well
Gilead's anti-viral expertise will stand it well
There is far more to biotech giant Gilead Sciences than its potential treatment for Covid-19; it has expertise in anti-virals against a wide range of …
14 Apr 2020